01 July 1997
Natural therapy of children with chronic persistent hepatitis B. Preliminary report
Dorota Sienkiewicz, Maciej Kaczmarski, Dariusz Marek LebensztejnMed Sci Monit 1997; 3(4): SR446-450 :: ID: 501492
Abstract
The subject of the study was a group of 10 children, aged 3-11 (2 girls, 8 boys), patients of the 3rd Department of Children Diseases of Medical Academy in Bia3ystok, who were diagnosed with chronic hepatitis type B. The etiology of this disease is infection with HB virus with the following immunologic profile: HBsAg(+), HBeAg(+), anti-HBs(-), anti-HBe(-). The ALAT activity (mean value - 55.0IU) and mean polymerase HBV DNA (4121.8cpm) activity were assessed prior to treatment; the patients showed cellular immunity disturbances. Natural anthroposophical drugs were administered in 4-week cycles as subcutaneous injections: Taraxacum Stanno cultum 0.1% (4 cycles), Hepar/Stannum D15/20 (8 cycles); and Hepatodoron as pills in daily doses. The patients were re-evaluated clinically every 3 months and ALAT and polymerase HBV DNA activity as well as cellular immunity and HBV markers were monitored every 6 months. After 12 months of therapy the following results were obtained: polymerase HBV DNA activity decreased in all of the patients to the mean value of 785.0cpm, sero-conversion in HBeAg/anti-Hbe markers occurred in 12.5% of the children and a tendency to normalization of the cellular immunity measured by rosette test occurred in 87.5% of the patients. These observations show that chronic hepatitis B is accompanied by the disorders of cellular immunity and that that natural drugs can influence the improvement of cellular immunity in patients with this type of hepatitis; they also seem to halt HBV replication which leads to full elimination of the virus from infected liver cells.
Keywords: chronic persistent hepatitis B, children, natural anthroposophical drugs, polymerase HBV DNA, cellular immunity
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952